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Background: International clinical trials are now rapidly expanding into Asia. However, the proportion of global
trials is higher in South Korea compared to Japan despite implementation of similar governmental support in both
countries. The difference in clinical trial environment might influence the respective physicians’ attitudes and
experience towards clinical trials. Therefore, we designed a questionnaire to explore how physicians conceive the
issues surrounding clinical trials in both countries.
Methods: A questionnaire survey was conducted at Kyoto University Hospital (KUHP) and Seoul National University
Hospital (SNUH) in 2008. The questionnaire consisted of 15 questions and 2 open-ended questions on broad key
issues relating to clinical trials.
Results: The number of responders was 301 at KUHP and 398 at SNUH. Doctors with trial experience were 196 at
KUHP and 150 at SNUH. Among them, 12% (24/196) at KUHP and 41% (61/150) at SUNH had global trial experience.
Most respondents at both institutions viewed clinical trials favorably and thought that conducting clinical trials
contributed to medical advances, which would ultimately lead to new and better treatments. The main reason raised
as a hindrance to conducting clinical trials was the lack of personnel support and time. Doctors at both university
hospitals thought that more clinical research coordinators were required to conduct clinical trials more efficiently.
KUHP doctors were driven mainly by pure academic interest or for their desire to find new treatments, while obtaining
credits for board certification and co-authorship on manuscripts also served as motivation factors for doctors at SNUH.
Conclusions: Our results revealed that there might be two different approaches to increase clinical trial activity. One is
a social level approach to establish clinical trial infrastructure providing sufficient clinical research professionals. The
other is an individual level approach that would provide incentives to encourage doctors to participate in and conduct
clinical trials.
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Industry-sponsored clinical trials have traditionally been
carried out in North America, Western Europe, and
Oceania. More recently, there has been an increase in
the globalization of clinical trials by the pharmaceutical
industry, especially for biological products [1]. Reasons
cited for this shift include the ability to reduce oper-
ational costs while recruiting a large number of patients
in a timely manner, the establishment of contact re-
search organizations focused on global clinical trials, the
expansion of market size, increased research capacity in
emerging countries, improvements in regulatory devel-
opment, and the harmonization of guidelines for clinical
practice and research [1]. Thus, international clinical tri-
als are now rapidly expanding into emerging countries
such as those in Eastern Europe, South America, and
Asia.
In compliance with the International Conference on
Harmonisation - Good Clinical Practice GCP (ICH-GCP)
in 1996 [2], the Japanese government established a minis-
terial ordinance on GCP in 1997 [3], which was imple-
mented in April of 1998. However, failure to provide a
proper infrastructure led to the continuous decrease in
domestic clinical trials with many of them being out-
sourced abroad. The 160 Japanese clinical trials held in
1993 plummeted to just 43 in 2001. With Japan being left
out of global clinical trials/global development, this came
to be known as the “hollowing out of clinical trials in
Japan”. As a consequence, Japan has been experiencing a
“Drug/Device Lag” phenomenon, where there is a delay in
the approval of new drugs and devices that are already ap-
proved in the US and in European countries [4,5]. To im-
prove this negative situation, the Ministry of Health,
Labour and Welfare (MHLW) of Japan has revamped
their clinical trial consultation system to establish an en-
vironment more conducive to clinical trials and to en-
hance the participation of Japan in global clinical trials
since 2003. The Japanese government launched a 3-year
(2003-2006) and a new 5-year clinical trial activation plan
(2007-2011) [6]. Improvements in policies to greatly
strengthen the review system have also been initiated [7].
Owing to these measures, the number of investigated new
drug (IND) applications in Japan increased from 361 in
2003 to 530 in 2007, 495 in 2008, and 553 in 2009 [8], and
the notorious drug lag has been cut in Japan from 3.4 years
in 2007 to 2 years in 2009, shrinking the approval time of
new drugs by almost half [9]. However, the proportion of
global trials in Japan still remains relatively low compared
with other Asian countries: 7.5% of the total in 2007,
15.6% in 2008, and 20.2% in 2009 [10].
In contrast, the number of domestic and global clinical
trials has been rapidly increasing in South Korea follow-
ing the introduction of the Korean (K)-GCP in 1996
leading to the separation of new-drug applications(NDAs) and INDs in 2000. In accordance with ICH-
GCP, a new K-GCP was implemented in 2001 [11,12].
These changes have all led to a Regional Clinical Trial
Centers (CTC) funding program supported by the Korean
Ministry for Health, Welfare and Family Affairs, which
has aided in the establishment of global standard GCP
CTCs in South Korea. In December 2007, the Regional
CTC funding program was expanded by the South
Korean government to meet the increasing demand for
clinical trials and the Korea National Enterprise for Clin-
ical Trials (KoNECT) was established. As a result, the
number of multinational sponsored clinical trials in
South Korea has dramatically increased from 5 in 2000
to 148 in 2007 and 216 in 2008, to the point where glo-
bal trials have exceeded the number of domestic clinical
trials [13].
Several studies have been performed to obtain a better
idea of Japanese physicians’ attitudes towards clinical re-
search [14,15]. Yanagawa et al. surveyed 89 doctors in
2000 and 62 doctors in 2004 at Tokushima University
Hospital, Japan [14]. Sumi et al. surveyed 310 physicians
in 2007 at Kyoto University Hospital (KUHP), Japan
[15]. Although the attitude towards participating in clin-
ical research was favorable, they felt that physicians
faced several barriers when initiating clinical studies
such as cumbersome paperwork and time constraints
[14,15]. To date, similar surveys regarding doctors’ atti-
tudes toward clinical research/clinical trials in South
Korea have not been reported.
It is matter of considerable concern that the growth in
the number of clinical trials in Japan and South Korea
has been different, despite implementation of similar
government-supported measures. The difference in the
clinical trial environment of each country might influ-
ence the respective physicians’ attitudes and experience.
Therefore, we designed a uniform questionnaire survey
to explore how individual physicians perceive the issues
surrounding clinical trials in two university hospitals in
Japan and South Korea: KUHP and Seoul National
University Hospital (SNUH). Elucidation of these differ-
ences may help facilitate recruitment of physicians in fu-
ture trials and thereby, help develop a better environment
for conducting clinical trials.
Methods
Study design
We conducted a questionnaire survey among physicians
in KUHP and SNUH between September and December
2008. Kyoto University had been designated as one of
seven distinguished research sites to participate in the
Coordination, Support and Training Program for Transla-
tional Research between 2007 and 2011, and most recently
the Second Stage Network Program for Accelerating Trans-
lational Research from 2012 through 2017 by the Ministry
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(MEXT) Japan. A total of 77 industry-sponsored trials ap-
proved by the KUHP Institutional Review Board (IRB)
were conducted in 2008, of which 14% were multinational
and 1.3% were Phase I trials. A total of 439 clinical studies
were approved by the KUHP ethics committee in 2008
and of those ~100 were investigator-initiated trials, which
were not aimed at drug approval.
SNUH comprises of a Main Hospital, Children’s Hos-
pital, Cancer Hospital, and the Biomedical Research In-
stitute and is one of the largest university hospitals in
South Korea. SNUH has been designated as one of the
qualified clinical trial facilities by the governmental
funding of the Regional CTC Program since 2004 and
the KoNECT Program since 2007. In SNUH, a total of
218 clinical trials were conducted in 2008, of which 37%
were multinational and ~20% were Phase I trials. ~100
investigator-initiated clinical trials were also approved by
the SNUH-IRB in 2008.
To optimize the response rate of the questionnaires, we
informed the directors of each of the 36 departments in
KUHP and 18 departments in SNUH to explain the study
protocol and to ask for their participation in the study.
Each department representative distributed the study de-
scription and questionnaire to all physicians belonging to
the department. Faculty, fellows, staff doctors (full time
physicians), residents, and doctoral students with medical
degrees were invited to participate. Approvals by The
Kyoto University Graduate School And Faculty of Medi-
cine Ethics Committee and The Seoul National Univer-
sity College of Medicine And Seoul National University
Hospital Institutional Review Board were obtained in
July 2008 as E-489 and June 2008 as C-0806-050-247,
respectively.
Development of questionnaire
We created new survey questions based on previously
conducted surveys regarding clinical studies for physi-
cians [14,15].
In a previous study, Yanagawa et al conducted an
opinion survey for physicians at Tokushima University
regarding their experience with industry. The aim of
their study was to explore the view of physicians towards
clinical trials for drug development, in order to improve
communication among participants, sponsors, and investi-
gators. The questionnaire started with asking the physicians
about their experience in conducting industry-sponsored
trials following the introduction of GCP in Japan in 1997.
Using 4 point scale, this was then followed by questions
aimed at revealing the general attitude of the physicians
towards industry-sponsored trials. Furthermore, the inves-
tigators were asked if they had faced any difficult situa-
tions during the industry-sponsored trial in several
subordinate items with multiple choice answers. Theinvestigators were also asked if they found merit in partici-
pating in industry-sponsored trials through an open-
ended question.
In another study, Sumi et al conducted a survey at
KUHP to investigate the willingness of physicians to
participate in clinical research. The aim of their study
was to identify methods of support and training that
assist physicians in conducting clinical research. The
target of interest of the survey was “clinical research”
which not only included industry-sponsored clinical
trials and academia-driven trials, but also “general
clinical research conducted by physicians” such as ob-
servational studies and epidemiological studies. They
inquired about the merits of participating in clinical
research and about the difficulties faced in conducting
such research using 5 and 9 multiple choice subor-
dinate items, respectively.
Our questionnaire survey for this study took into con-
sideration the past two surveys and focused on clinical
trials (including trials conducted by industry as well as
academia). In light of the recent increase in multi-
national clinical trials, the items related to global trials
were asked separately. The term “clinical trial” used in
this survey was not categorized by study design or fund-
ing body and thus, the definition of “clinical trial” in this
survey included all randomized controlled trials, non-
randomized trials, pharmaceutical-sponsored trials, and
investigator-initiated trials. We inquired through a 4 tier
scale about the merits of participating in clinical trials
(Question #8) and about the difficulties faced in con-
ducting such trials (Question #10) using 10 and 11 sub-
ordinate items respectively. Furthermore, regarding
multi-national clinical trials sponsored by a global
pharmaceutical company, we inquired if they had experi-
ence in participating in such a trial and if so, then
through an 8 subordinate-item question via a 4 tier scale
asked about the major obstacles in participating in a
multi-national trial (Question #16). The questionnaire
was first constructed in English and subsequently trans-
lated into Japanese and Korean before distribution at
both institutions. The questionnaire was anonymous and
contained 5 pages in English, 5 pages in Japanese, and 4
pages in Korean. The questionnaire is available online
(see Additional file 1).
Statistical analysis
Data were summarized as the frequency of each answer
and their proportion. Each subordinate item in Ques-
tions #8, 10, 14 and 16 was treated as a binary variable
for statistical analysis. Fisher’s exact tests were used for
the comparison between hospitals. All reported p values
are two-tailed, and p < 0.01 was taken to indicate statis-
tical significance. Statistical analysis was performed using
SAS Version 9.2 (SAS Institute, Cary, NC, USA).
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the questionnaire
Categorization of the answers from the open-ended
questions (Question #9 and #17) were performed in fol-
lowing manner. First, a researcher (TI) and an ethics re-
searcher (TH) extracted pieces of comments from all
transcripts. Then, under the supervision of a psycholo-
gist (KN), the researchers carefully conceptualized and
categorized the attributes from the comments and cre-
ated a definition of each category for all the attributes.
Results
Characteristics of respondents and their interest level and
experience in clinical trials
There were a total of 1,091 physicians in KUHP at the
time of the survey (345 faculty, 181 staff doctors, 133
junior residents, and 432 PhD students in the depart-
ment of clinical medicine). There were a total of 1,661
doctors at SNUH at the time of the survey (420 faculty,
257 fellows, 777 residents, and 207 interns).
34 out of 36 departments in KUHP and all 18 depart-
ments in SNUH consented to participate in this survey.
We were not able to get any response from the directors
of the Department of Endocrinology and Metabolism
and the Department of Medical Informatics at KUHP
for reasons not known to us. The departments consisted
of 11 faculty members and 8 staff doctors in total at the
time of the survey.
Among 471 physicians from the 34 departments at
KUHP, a total of 301 (64%) completed the questionnaire.
Among 882 physicians from the 18 departments in
SNUH, a total of 398 (45%) completed the questionnaire.
Table 1 presents the characteristics of respondents and
their interest level and experience in clinical trials. In
KUHP, 10%, 52%, 32%, and 6% of respondents were in
their 20s, 30s, 40s, and over 50, respectively. Females
represented 17% (50/301) of KUHP respondents. A total
of 169 faculty (56%) and 132 non-faculty (staff doctors,
residents and PhD students) members responded. In
SNUH, 44%, 42%, 8%, and 7% of respondents were in
their 20s, 30s, 40s, and over 50, respectively. Females
represented 37% (147/398) of all SNUH respondents. A
total of 90 faculty (23%) and 308 non-faculty (fellows,
residents and PhD students) members responded. In
KUHP, faculty members were more likely to complete
the survey than non-faculty members and the converse
was true at SNUH. There were a greater proportion of
young physicians answering the survey at SNUH com-
pared to KUHP.
Physicians with experience in clinical trials represented
196 out of 301 (65%) at KUHP and 150 of 398 (38%) at
SNUH (Table 1). Overall, there was no major difference
in the specialities and the respondents’ roles in previous
clinical trials between the two university hospitals.Among doctors with previous clinical trial experience,
29% and 33% at KUHP and SNUH, respectively, had re-
cent experience as principal investigators. 12% and 41%
of doctors with clinical trial experience at KUHP (24/
196) and SNUH (61/150), respectively, were involved in
global clinical trials.
Physicians’ interest in clinical trials
90% and 78% of all respondents at KUHP and SNUH,
respectively, showed interest in conducting clinical trials
(Table 1). Together a large proportion of physicians with
previous clinical trial experience and many doctors with-
out clinical trial experience expressed high interest in
conducting clinical trials.
94% and 70% of all doctors at KUHP and SNUH, re-
spectively, stated that they would be willing to partici-
pate or help (if time permits) in clinical trials organized
by other doctors (Question #7).
Time for informed consent
In Question #6, doctors with previous clinical trial ex-
perience stated how long it took them to obtain in-
formed consent from study participants. In KUHP, 31%
(60/196), 34% (67/196), 31% (61/196), and 3% (6/196)
took <15 minutes, 15-30 minutes, 30-60 minutes, and
>1 hour to obtain informed consent, respectively. In
SNUH, 47% (71/150), 36% (54/150), 9% (15/150), 0% (0/196)
took <15 minutes, 15-30 minutes, 30-60 minutes, and
>1 hour to obtain informed consent, respectively.
The merits of conducting clinical trials for doctors
In Question #8, the participants were asked to rate on a
4-tier scale 9 structured items that might be perceived as
benefits for doctors in performing clinical trials. Add-
itional comments were allowed to be entered by freehand.
301 and 398 doctors at KUHP and SNUH, respectively,
responded to the question (Figure 1). At KUHP, the high-
est rated benefits (items rated as either “strongly agree”
and “agree”) in decreasing order were: the contribution to
medical progress (97%), helping patients with new treat-
ments (97%), obtaining a wider and deeper understanding
of diseases (87%), and the opportunity to publish their
findings (57%). At SNUH, the highest rated benefits were:
helping patients with new treatments (86%), obtaining
credits for board certification (80%), the opportunity to
publish their findings (79%), and the contribution to med-
ical progress (78%). There was a significant difference be-
tween KUHP and SNUH in their opinions on performing
clinical trials to obtain board certification, as this was least
important determinant for doctors at KUHP (p < 0.01). 19
(6%) doctors at KUHP and 51 (13%) at SNUH thought
that conducting clinical trial was just a waste of time and
energy. No additional freehand comments were entered
by any of the participants at KUHP or SNUH.















% (n) % (n) % (n) % (n)
(196) (104) (301)* (150) (242) (398)*
Age range
<=29 6 (12) 17 (18) 10 (30) 19 (29) 59 (143) 44 (175)
30-39 44 (86) 66 (69) 52 (156) 47 (70) 39 (94) 42 (166)
40-49 42 (83) 13 (14) 32 (97) 18 (27) 1 (2) 8 (30)
> = 50 8 (15) 3 (3) 6 (18) 16 (24) 1 (3) 7 (27)
Gender (Female ratio) 13 (25) 24 (25) 17 (50) 25 (38) 45 (109) 37 (147)
Faculty 70 (138) 30 (31) 56 (169) 51 (76) 5 (13) 23 (90)
Majority of Doctors
Internal Medicine** 36 (71) 30 (31) 34 (102) 23 (35) 16 (38) 19 (75)
Surgery*** 21 (41) 11 (11) 17 (52) 3 (5) 12 (28) 9 (34)
Ophthalmology 8 (16) 10 (10) 9 (27) 7 (10) 5 (12) 6 (22)
Dental Surgery 4 (8) 15 (16) 8 (24) 1 (2) 1 (2)
Otolaryngology 5 (10) 8 (8) 6 (18) 5 (8) 4 (10) 5 (18)
Radiology**** 6 (11) 3 (3) 5 (14) 14 (21) 12 (30) 13 (51)
Gynecology 3 (5) 7 (7) 4 (12) 7 (11) 5 (13) 6 (25)
Psychiatry 3 (5) 3 (3) 3 (8) 7 (10) 11 (27) 9 (37)
Orthopedics 3 (6) 1 (1) 2 (7) 5 (7) 9 (21) 8 (30)
Dermatology 3 (5) 2 (2) 2 (7) 7 (11) 2 (6) 4 (17)
Urology 3 (6) 2 (6) 5 (7) 3 (8) 4 (15)
Pediatrics 2 (3) 1 (1) 1 (4) 5 (7) 8 (20) 7 (27)
Others***** 5 (9) 11 (11) 7 (20) 9 (14) 10 (25) 10 (39)
Blank 1 (2) 2 (4) 2 (6)
The role in the latest clinical trial
As principle investigators 29 (57) 33 (50)
As co-investigators 46 (91) 44 (66)
As sub-investigators 22 (44) 13 (19)
As othres 2 (3) 8 (12)
Blank 1 (1) 2 (3)
Experience in global clinical trial
12 (24) 41 (61)
Interests
Drs who are interested in clinical trials 95 (186) 80 (83) 90 (270) 90 (135) 71 (172) 78 (310)
Drs who are not interested in
clinical trials
5 (10) 18 (19) 10 (29) 9 (14) 29 (70) 22 (87)
Blank 2 (2) 1 (2) 1 (1) 0 (1)
*In total 7 (1 in KUHP and 6 in SUNU) doctors did not state their past experience in clinical trials.
**Internal Medicine in KUHP were hematology, cardiovascular medicine, gastroenterology, respiratory medicine, rheumatology, diabetic mellitus and nutritional
medicine, nephrology, neurology, and geriatric medicine. Internal Medicine in SNUH were general internal medicine and immunology.
***Surgery in KUHP were gastrointestinal surgery, breast surgery, hepato-bilialy pancreatic surgery, transplantation surgery, neurosurgery, plastic surgery,
cardiovascular surgery, and respiratory surgery. Surgery in SNUH were general surgery and cardiovascular surgery.
****Radiology in SNUH were radiology and radiation oncology.
***** Others in KUHP were Pathology, Emergency Medicine, Anesthesiology, Central clinical laboratory, and Transfusion Medicine & Cell Therapy. Others in SNUH
were Pathology, Emergency Medicine, Family Medicine, Preventive Medicine, Clinical Pharmacology, and Rehabilitation Medicine.
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Figure 1 The merits of conducting clinical trials for doctors. (KUHP, n = 301; SNUH, n = 398). In Question #8 “What do you think are the
merits of conducting clinical trials?”, the participants were asked to rate nine items by how strongly they agree using the following 4-tier scale:
strongly agree, agree, partially agree, and disagree. The proportion of doctors responding as “strongly agree and agree” and “partially agree and
disagree” in each institution was compared. 301 doctors at KUHP and 398 doctors at SNUH responded to the question.
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In Question #10, the physicians were asked about poten-
tial problems they faced in conducting clinical trials by
rating 10 factors on a 4-tier scale. Among the subordin-
ate items, ‘systemic support from the hospital’ refers to
personnel support such as research nurses, supporting
entities and the general support environment provided
to doctors not only for clinical trials but also for day-to-
day clinical practice. This should be distinguished from
the subordinate item ‘infrastructure’ which refers to the
specialized support system during clinical trials involving
trained clinical trial professionals. We also distinguished
‘enrolment of trial participants’ from ‘problem with
obtaining informed consent’ in items #7 and #8 of this
question. ‘Enrolment of trial participants’ refers to diffi-
culties in patient recruitment because of safety concerns
and the eligibility criteria. Difficulties in ‘obtaining in-
formed consent’ specifically related to difficulties in the
interaction between the patient and the doctor. Add-
itional comments were allowed to be entered by free-
hand. 196 and 150 doctors with clinical trial experience
at KUHP and SNUH, respectively, responded to this
question (Figure 2). The fraction of doctors rating the
items as either “a serious problem” or “a problem” were:
shortage of clinical research coordinators/research
nurses (KUHP 94%, SNUH 65%; p < 0.01), lack of time
(KUHP 91%, SNUH 69%; p < 0.01), insufficient infra-
structure (KUHP 89%, SNUH 57%; p < 0.01), lack of sys-
temic support from the hospital (KUHP 86%, SNUH
57%; p < 0.01), difficulties with data management/statis-
tical analysis (KUHP 82%, SNUH 47%; p < 0.01), inad-
equate funding (KUHP 79%, SNUH 49%; p < 0.01),
difficulties with enrolment of trial participants (KUHP
78%, SNUH 54%; p < 0.01), difficulties in communication
with the ethical or IRB committees (KUHP 68%, SNUH
24%; p < 0.01), obtaining of informed consent (KUHP56%, SNUH 35%; p < 0.01), and lack of communication
with the trial sponsor (KUHP 37%, SNUH 19%; p <
0.01). No additional freehand comments were entered
by any of the participants at KUHP or SNUH. Overall,
doctors at KUHP appeared to encounter greater difficul-
ties than doctors at SNUH, as over 70% of doctors at
KUHP felt that they have limited resources including
personnel (clinical research coordinators/research nurses,
data manager and statistician), time, infrastructure, sys-
temic support, and funding.
In Question #9, the physicians were asked about their
experiences in clinical trials that underwent earlier ter-
mination than scheduled by the research protocol. The
reasons of early termination were entered by freehand.
53 doctors at KUHP (27% of 196 doctors who have clin-
ical trial experience) and 27 doctors at SNUH (16% of
150 doctors who have the experience) previously experi-
enced an early termination of clinical trials. At KUHP,
the reasons of the early termination of trials obtained by
freehand were categorized and included the following in
decreasing order of frequency: limited enrolment of trial
participants (55%, 29/53), occurrence of adverse events
(8%, 4/53), insufficient infrastructure (for example, lim-
ited access to imaging or testing devices) (6%, 3/53),
negative analysis of interim results (4%, 2/53), transfer of
doctors (4%, 2/53), difficulties in obtaining informed
consent (4%, 2/53), shortage of staff (2%, 1/53), difficul-
ties in long-term follow-up (2%, 1/53), and insufficient
funding (2%, 1/53). The reasons at SNUH in decreasing
order were occurrence of adverse events (26%, 7/27),
limited enrolment of trial participants (19%, 5/27), in-
terim analysis (15%, 4/27), at the sponsor’s request (15%,
4/27), protocol violation (11%, 2/27), publication of a
similar clinical trial result by another institution (4%, 1/27),
and unfeasible research design (4%, 1/27). There are
many differences in the clinical trials conducted at
Figure 2 Major problems faced by doctors with clinical trial experience (KUHP, n = 196; SNUH, n = 150). In Question #10 “What are the
major problems in conducting clinical trials?”, the participants were asked to answer the question according to the level of seriousness: a serious
problem, a problem, a small problem, and no problem. The proportion of doctors responding as “a serious problem and a problem” and “a small
problem and no problem” in each institution was compared. 196 doctors at KUHP and 150 doctors at SNUH with clinical trial experience responded to
this question.
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signs, diseases, and the investigational agents (drug, de-
vice, biological) being tested. The higher fraction of
adverse events observed at SNUH may be due to the
higher risk profile of the trials there.
Experiences and major obstacles faced in multinational
clinical trials
In Question #16, the participants were asked about their
experiences in multinational clinical trials sponsored by
a global pharmaceutical company. 12% (24/196) at
KUHP and 41% (61/150) at SNUH of doctors with clin-
ical trial experience were involved in such multinational
clinical trials (Table 1). Of those who possessed global
clinical trial experience, we further asked them to rateFigure 3 Obstacles in multinational clinical trials. In Question #16, the
potential obstacles faced in a multinational clinical trial by their level of ser
small problem, and no problem. The proportion of doctors responding as
lem” in each institution were compared. 24 and 61 doctors with global clin
the question.on a 4-tier scale 7 different potential obstacles that were
faced in their participation in multinational clinical trials
(Figure 3). Additional comments were allowed to be en-
tered by freehand. 79% of global trial-experienced doc-
tors at KUHP thought that the lack of infrastructure for
clinical trials is most problematic, followed by differ-
ences in medical systems of different countries (63%),
the regulation process and legal system (58%), and the
quality of the clinical trial (54%). Cost-effectiveness, the
qualifications of the investigator, and language barriers
were considered obstacles by less than 50% of the multi-
national clinical trial-experienced doctors at KUHP. In
contrast, only 25% of doctors with global trial experience
at SNUH viewed the infrastructure and the quality of
clinical trials as problematic. Moreover, only 41% ofparticipants with global clinical trial experience were asked to rate 7
iousness according to a 4-tier scale: a serious problem, a problem, a
“a serious problem and a problem” and “a small problem and no prob-
ical trial experience at KUHP and SNUH, respectively, were answered in
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the regulation process and legal system were obstacles.
Overall, <50% of global clinical trial-experienced doctors
at SNUH considered any of the 7 items as obstacles. By
freehand, one doctor in KUHP specified the difference
in diagnostic criteria between countries as an obstacle
that poses “a serious problem”.
The knowledge of doctors at KUHP and SUNH regarding
clinical trials
The participants were questioned whether they recog-
nized the principles of the World Medical Association
Declaration of Helsinki in Question #11 and were subse-
quently asked 4 true or false questions relating to the
declaration in Question #12. Among all respondents,
97% and 74% of doctors at KUHP and SNUH, respect-
ively, stated that they had knowledge of the declaration.
63% and 57% at KUHP and SNUH, respectively, answered
all the questions related the declaration correctly.
When asked about their sources of information relat-
ing to clinical trials in Question #13, 569 answers from
297 doctors at KUHP and 433 answers from 380 doctors
at SNUH were obtained. 283 and 198 doctors at KUHP
and SNUH, respectively, answered that they have oppor-
tunities to acquire this information from various sources
including domestic seminars and lectures, international
educational programs, and clinical trial journals (Figure 4).
The conditions and personnel required for overcoming
the obstacles faced in clinical trials at KUHP and SNUH
In Question #14, we asked the doctors to rate on a 4-tier
scale 6 factors that were thought to be critical in overcom-
ing the obstacles for the development of clinical trials. 196
and 150 doctors at KUHP and SNUH, respectively, who
have clinical trial experience responded to this question
(Figure 5). The fraction of doctors rating the items as
either “very important” or “important” were: financialFigure 4 Sources of information relating to clinical trials. When asked
trials in question #13, 569 answers from 297 doctors at KUHP and 433 answ
with clinical trial experience and 3 of doctors without clinical trial experien
doctors without experience, and a doctor who did not state their trial expesupport to improve the quality of clinical trials (KUHP
98%, SNUH 85%; p < 0.01), training specialized people for
running clinical trials (KUHP 97%, SNUH 91%; p = 0.03),
reforming the system and regulatory rules (KUHP 96%,
SNUH 82%; p < 0.01), establishment of clinical trial cen-
ters (KUHP 91%, SNUH 75%; p < 0.01), establishing good
training programs for clinical trials (KUHP 89%, SNUH
83%; p = 0.17), and enhancing public awareness of clinical
trials (KUHP 87%; SNUH 80%; p = 0.08).
In Question #15, among the 5 different types of person-
nel required for running clinical trials (investigators, clin-
ical pharmacologists/pharmaceutical physicians, clinical
research coordinators/research nurses, data managers/bio-
statisticians, qualified regulatory government officials), we
asked the doctors who they thought the most effort
into training should be placed (Figure 6). Clinical trial-
experienced doctors at both university hospitals thought
that the most important personnel were clinical re-
search coordinators/research nurses: 47% of answers at
KUHP (108/228) and 44% of answers at SNUH (64/104).
However, doctors who did not have prior clinical trial ex-
perience at KUHP answered data manager and biostatisti-
cian as the most important (34%, 37/109 answers), and
those doctors at SNUH answered principal investigator as
the most important (36%, 84/235 answers).Additional open-ended comments from respondents
We welcomed additional comments by freehand in
Question #17. 24 doctors out of 301 (8%) in KUHP and
13 doctors out of 398 (3%) in SNUH responded to the
open-ended question. Among those who responded, 17
doctors at KUHP and 8 doctors at SNUH had clinical
trial experience. A total of 41 comments from 24 doctors
at KUHP and 15 comments from 13 doctors in SNUH
were received. The comments were separated into 8 cat-
egories as shown in Table 2. In Question #17, KUHP
doctors tended to provide negative comments aboutabout the place where they acquired knowledge related to clinical
ers from 380 doctors at SNUH were obtained. 4 doctors (a doctor
ce) at KUHP and 18 doctors (6 doctors with clinical trial experience, 11
rience) at SNUH did not respond to the question.
Figure 5 Necessary conditions for overcoming the obstacles in conducting clinical trials at university hospitals. In Question#14 “What do
you think is important for overcoming the obstacles for the development of clinical trials?”, the participants were asked to rate 6 items by
importance: very important, important, partially important, and not important. The proportion of doctors responding as “very important and
important” and “partially important and not important” in each institution were compared. 196 doctors in KUHP and 150 doctors in SNUH with
clinical trial experience responded to this question.
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and the lack of support not only for clinical trials but
also in daily clinical practice. In contrast, SNUH doctors
tended to give more positive comments towards clinical
trials, providing specific proposals for promoting clinical
trials.
For example, in category C1, one KUHP doctor stated:
Neither coordinators nor nurses help us in the outpatient
clinics in the university hospital with our usual clinical
practice. We need to call patients, draw blood, and book
the patient’s next visit ourselves. In addition, we don’t
receive enough help in the inpatient ward either. Working
under these terrible conditions, I don’t have any positive
feelings to cooperate in clinical trials.
Similar comments relating to the lack of time, per-
sonnel support from the hospital, and infrastructureFigure 6 Specialized training programs necessary for development of
personnel required for running clinical trials (investigators, clinical pharmac
research nurses, data managers/biostatisticians, qualified regulatory govern
effort into training should be placed. Answers from 196 doctors with and 1
Answers from 150 doctors with and 242 doctors without clinical trial experwere noted in 9 out of 20 KUHP comments in category
C1. There were also constructive comments in this cat-
egory, which stated the necessity of clinical research co-
ordinators (2), biostatisticians (4), better qualifications of
reviewers in authorities (1), and improved infrastructure
with sufficient personnel support (4).
In category C1, a SNUH doctor commented about the
necessity of a data manager. Another SNUH doctor
pointed out that the quality of the infrastructure varies
widely among Korean sites:
The sites that can actually accomplish multicenter trials
are rare and clinical trial infrastructures are fragile
except for major large hospitals in Korea.
In category C2 of Question #17, 3 KUHP doctors
mentioned difficulty in recruitment of patients. 2 KUHP
doctors stated their reluctance to offer their help inpersonnel. In Question #15, among the 5 different types of
ologists/pharmaceutical physicians, clinical research coordinators/
ment officials), the doctors were asked who they thought the most
04 doctors without clinical trial experience were obtained from KUHP.
ience were obtained from SNUH.
Table 2 Additional open-ended comments from respondents (N = 37)
KUHP SNUH
The number of responding doctors 24 13
Total number of comments 41 15
Categories
C1 Lack of time, personnel support, and infrastructure 20 2
C2 Difficulties in recruitment of participants 13 6
C3 No benefit for individual doctors to engage in clinical trials 3 0
C4 Demand for education of investigators 2 1
C5 Necessity of clinical trials that fulfill the doctor’s academic interest 0 3
C6 Importance of funding 0 1
C7 Significance of global trials as a national strategy 0 2
C8 Criticism against this questionnaire 3 0
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roles as clinicians versus investigators and its impact on
their patient/doctor relationship. 4 KUHP doctors stated
the patients’ reluctance to be recruited to clinical trials
in Japan. A SNUH doctor mentioned difficulty in patient
recruitment and recommended the establishment of a
more efficient patient referral system to SNUH from
other hospitals. Both KUHP and SNUH doctors agreed
on the necessity of public relations for increasing re-
cruitment of participants. However, a KUHP doctor
raised concerns about a negative news report against
clinical trials, which has discouraged doctors from par-
ticipating in clinical trials.
In category C5 of Question #17, it was important to
note that a SNUH doctor stated that clinical trials in
South Korea tend to be motivated only by commercial
interests. 2 other SUNH doctors stated their desire to
conduct clinical trials that answer academic research
questions. Similar comments were not obtained from re-
spondents at KUHP.
In category C7, a SNUH doctor emphasized the im-
portance of global trials as a national strategy in Korea
and another SNUH doctor proposed that the generalized
standard operating procedure acceptable by international
standards should be developed for international audit.
Discussion
Main findings of the survey study
Doctors in both university hospitals, who participated in
this study, expressed much enthusiasm in the execution
of clinical trials. A large proportion of doctors at KUHP
and SNUH already had past and/or present experience
in conducting clinical trials. 12% and 41% of doctors
with clinical trial experience also had experience in glo-
bal clinical trials at KUHP and SNUH, respectively. The
majority of doctors at both university hospitals believed
that conducting clinical trials contributes to medical ad-
vances, which would ultimately lead to new and bettertreatments for patients. Time constraints and short-
handedness of clinical research coordinators/research
nurses represented the greatest obstacles in conducting
clinical trials for doctors at both institutions. In general,
compared to SNUH, a greater number of physicians at
KUHP felt that there were more obstacles than incen-
tives to conduct clinical trials.
Social issues: lack of an adequate infrastructure,
personnel, time, operational support, and public relations
as an obstacle in running clinical trials
The lack of an adequate infrastructure was believed to
be an obstacle for conducting clinical trials by 89% of all
trial-experienced doctors and 79% of global trial-
experienced doctors at KUHP. This was in contrast to
SNUH, where only 57% of all trial-experienced doctors
and 25% with global trial experience considered this a
problem. Moreover, 91% of KUHP compared to 75% of
SNUH trial-experienced doctors stated that the estab-
lishment of clinical trial centers would be important.
The differences in views between the Japanese and South
Korean doctors might be explained by the success of the
South Korean government in creating the necessary infra-
structure for conducting clinical trials such as the estab-
lishment of 15 Regional Clinical Trial Centers (RCTCs).
KFDA allows clinical trials to be conducted only in the
150 KFDA-accredited hospitals and the RCTCs supported
by the South Korean government are all large university
hospitals capable of recruiting patients effectively for clin-
ical trials. In contrast, the quality of hospitals in Japan is
uniform, each with limited numbers of patients that are
scattered throughout Japan, making patient recruitment
into clinical trials difficult. This notion is consistent with
the fact that more doctors at KUHP, compared to doctors
at SNUH, viewed patient recruitment as a major obstacle
in running clinical trials.
Doctors at both university hospitals thought enhancing
public awareness of clinical trials was required for
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lations is the issue in Japan. Saito et al reported that 50%
of patients in general and 70% of all participants in clin-
ical trials stated that the amount of information regard-
ing clinical trials is scarce, and people perceive that the
information services related to clinical trials to be insuf-
ficient in Japan [16]. Takita et al reported that many
Japanese news reports emphasize the performance of
pharmaceutical companies and incidents of misconduct,
such as medication scandals, while providing insufficient
information regarding clinical trials [17]. In fact, a doc-
tor at KUHP in our study specifically commented on a
recent negative news report on clinical trials, which has
discouraged doctors’ from participating in clinical trials.
Another possible reason for difficulties in enrolment of
trial participants is the patients’ reluctance. Although
both Japan and South Korea have a universal health in-
surance system with free medical access, differences in
co-pays, reimbursement rates, and treatment regulations
might make Japanese doctors more hesitant to offer pa-
tients to be recruited into clinical trials [18,19]. In the
open-ended question of this survey, 4 KUHP doctors
commented on the patients’ reluctance to be recruited
to clinical trials in Japan.
Another major obstacle for doctors in conducting clin-
ical trials was the lack of time. This is likely because of
the shortage of doctors in Japan and South Korea. Ac-
cording to the World Health Organization data of
World Health Statistics 2011, the number of physicians
per 10,000 populations was 21 in Japan and 17 in South
Korea, ranked at 59th and 63rd, respectively out of 193
nations in the world [20]. These doctors need to cover
the large number of hospital beds in Japan and South
Korea, which are conversely ranked at 1st and 3rd in the
world, respectively [20]. Similar problems were raised by
Japanese doctors at KUHP in a survey conducted by
Sumi et al [15]. Difficulties are compounded by the fact
that most hospitals are not equipped with staff to
streamline patient recruitment and manage the neces-
sary paperwork, so the work continues to burden the
already time-strapped doctors.
Nearly 80% of KUHP doctors with clinical trial experi-
ence thought that there was insufficient support from
their hospital. However, at SNUH, only a little more
than half of trial-experienced doctors believed that this
was a problem. These findings were corroborated by
additional comments from 9 KUHP doctors, who stated
that there was a lack of personnel support from the hos-
pital not only for clinical trials but also in their daily
clinical practice.
A large majority of doctors from both institutes thought
that the establishment of better training programs for run-
ning clinical trials is necessary to increase the number of
skilled personnel. In addition, trial-experienced doctors atboth KUHP and SNUH thought that they needed more
clinical research coordinators/research nurses to conduct
clinical trials more efficiently. The provision of sufficient
study personnel or research nurses, who can regularly
contact the participating physicians, might be the most ef-
fective intervention in overcoming this barrier.
The major obstacle other than infrastructure in par-
ticipation in global trials for KUHP doctors was quality
of the global clinical trial. 54% of KUHP doctors com-
pared to only 25% of SNUH doctors stated that the qual-
ity of the clinical trial was an obstacle. This was
unrelated to a potential language barrier that may exist
in global trials, which was not perceived as an obstacle
for many doctors at both KUHP and SNUH. Although
the actual quality of clinical trials does not differ in both
countries, the differing answers regarding quality may be
explained by the fact that KUHP has less infrastructure,
and fewer personnel and investigators who are experi-
enced in multinational trials than SNUH. Because of
their less experience in multinational clinical trials,
KUHP investigators might be unaccustomed to the dif-
ferences in the rules and regulations of document hand-
ling applied in global clinical trials compared to those in
Japan. Therefore it is likely that KUHP doctors may be
compelled to have more rigid perception in regarding
the quality of trials or might have higher expectations
when participate in multinational clinical trials.
Pharmaceutical industry sponsored trial vs. academia
initiated trial
There are two types of clinical trials which intervene
with the clinical care of patients: development trials
undertaken by pharmaceutical companies for the purpose
of drug licensing approval, and post-approval studies
mostly led by physicians/investigators. In trials conducted
by drug companies, the scope of the study is limited as the
trial is designed to obtain approval of their therapy for the
indicated disease, which is dictated by regulatory require-
ments. Thus, this necessitates investigator-led post mar-
keting trials for the advancement of medical science and
treatment [21].
When conducting investigator-initiated trials in Japan,
it is necessary to be compliant to The Ethics Guideline
for Clinical Studies (EGCS) established by the Ministry
of Health, Labour Welfare of Japan. The EGCS had been
amended in July 2008 and was implemented in April
2009 to establish high-quality clinical study and
evidence-building from clinical research findings [22].
When we conducted the questionnaire survey between
September and December 2008, the level of interest for
investigator-initiated trials and the EGCS was high
amongst physicians [23]. It was likely that physicians at
KUHP were feeling uncertain about changing their clin-
ical trial environment due to the amendment in the
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from KUHP doctors for this survey might reflect the is-
sues relating academia led clinical trials rather than in-
dustry sponsored trials.
On the contrary, the greater proportion of doctors
with global clinical trial experience at SNUH compared
to KUHP possibly reflects the dramatic increase in glo-
bal clinical trials in South Korea. Therefore, the re-
sponses from SNUH might reflect the issues in relation
to those global trials. A SNUH participant in our study
expressed her concern that clinical trials in South Korea
tend to be motivated only by commercial interests, and
2 other SNUH doctors wished to conduct more clinical
trials which aim to find answers to academic research
questions.
Awareness of issues surrounding clinical trials at the
individual level
The process of obtaining informed consent was a huge
burden for 55% of doctors at KUHP. In contrast, only
35% of doctors at SNUH felt that informed consent was
a major obstruction in conducting clinical trials. We also
found that doctors at KUHP took more time to obtain
informed consent from study participants than those at
SNUH. The difference might be explained in part by the
higher proportion of Phase I trials at SNUH compared
to KUHP, as the content of informed consent is different
between Phase I trial and trials that have moved further
along. There were 218 industry-sponsored trials in
SNUH and ~20% of them were the Phase I trials,
whereas of the 77 industry-sponsored trials at KUHP
only 1 trial (1.3%) was a Phase I trial in 2008 at the time
of the survey. There might be other factors as to why
physicians face difficulties in obtaining informed consent
of which one is “conflict of interest” [24,25]. Although
our questionnaire did not specifically ask about opinions
on potential conflicts of interest, 2 KUHP doctors com-
mented on their reluctance to offer help to randomized
controlled trials because of the difficulty in separating
their conflicting role as a clinician versus an investigator,
which might affect their patient/doctor relationship. In
addition to conflicts of interests, a “defensive attitude” to
avoid lawsuits may contribute to lengthening the time
needed for informed consent. KUHP doctors may tend
to explain everything about the clinical trial in an obses-
sive manner in their desire in not wanting to leave out
anything unexplained. Cultural differences may also play
a role in the increased time needed for obtaining in-
formed consent. KUHP doctors may not acquire profi-
ciency in obtaining informed consent because of the
cultural gap between contractual relationships and
affective trust [26,27]. Together, we believe that multiple
factors could contribute to the perception that informed
consent was a major obstruction in conducting clinicaltrials. However, in our study, we did not address any
questions in matters relating to the deep personal feel-
ings of physicians in obtaining informed consent, and
thus we are not able to throw any light on the compari-
son between the opinions of physicians regarding this
matter in both the university hospitals.
Although physicians faced many obstacles in conduct-
ing clinical trials, our results indicated that the majority
of them from both university hospitals were quite willing
to conduct clinical trials. This is in agreement with a
previous survey in 2007 at KUHP, where 97% of all re-
spondents believed that clinical research is necessary for
physicians [15]. Compared to SNUH, doctors at KUHP
showed a more cooperative attitude toward clinical trials
operated by other doctors. The high interest level in
clinical trials seen in physicians is reassuring, although it
has been thought that university researchers in Japan
prefer basic research to clinical studies [28].
As previously pointed out, physicians should be stimu-
lated to feel a sense of commitment to medical innova-
tion so as to enhance their participation in clinical
research [29,30]. Doctors from both universities believed
that the major benefits achieved from clinical trials were
contribution to medical advances and the ability to pro-
vide new treatments to patients. While KUHP doctors
were driven mainly by pure academic interest or for their
desire to find new treatments for their patients, obtaining
credits for board certification and co-authorship on manu-
scripts also served as motivation factors for doctors at
SNUH. Board certification at SNUH allowed the doctors
to be recognized as special experts and competent physi-
cians in their medical specialties. However, these matters
were not regarded as incentives for doctors at KUHP.
The knowledge of doctors regarding clinical trials
Based on our questionnaire survey, we found that SNUH
doctors possessed relatively less knowledge about the
Helsinki declaration compared to KUHP and thus had
fewer opportunities to obtain information about clinical
trials. A possible reason for such a result may be attrib-
uted to the younger age of the respondents in SNUH
compared to KUHP. Regarding Question #13 which re-
lates to where one acquires information regarding indi-
vidual clinical trial methods and results, we did not have
a separate question asking about mandatory regulatory
education and training related to execution of clinical
trials. In addition, we had not incorporated any queries
that could compare the type of educational seminars at
KUHP and SNUH at the time of the survey. Conse-
quently, we are unable to give an overview of the type of
clinical trial educational training available at both uni-
versity hospitals. Therefore, it is not possible for us to
compare the results related to the existence or non-
existence of knowledge related to clinical trials.
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SNUH went on to develop a mandatory course on GCP
and research ethics for every medical student at Seoul
National University Medical School in 2010. Further-
more, as of 2011 it is mandatory for every investigator
including research staff and research nurses at SNUH to
take at least one GCP course per year to conduct clinical
research. Various types of clinical trial-related informa-
tional and educational material are now being provided
to SNUH investigators through seminars, classes, pam-
phlets as well as educational websites since 2011 [31].
Strengths and weaknesses of the present study
We believe our present study possesses several strengths.
First, to our knowledge this is the first international sur-
vey designed to compare the attitudes of physicians to-
ward clinical trials in Japan and South Korea. This was
performed by concurrently administering an identical
questionnaire survey for doctors at KUHP and SNUH,
which are considered representative university hospitals
in Japan and South Korea. Second, although there have
been several studies reporting the views of physicians on
specific clinical trials, there have only been a few studies
that have conducted a survey about their general opin-
ion on clinical trials in an university hospital setting.
Third, this questionnaire was designed by the authors
who support other doctors in conducting clinical trials
in the academic research organizations of each university
hospital, which allowed the survey to be focused on key
issues regarding clinical trials. Therefore, the method of
creating the questionnaire in this way itself was explora-
tory and has helped us to hone in on key issues sur-
rounding clinical trials. Thus, through this survey, we
believe that we have been able to identify the major is-
sues that surround clinical trials conducted by physi-
cians, which is an understanding vital for improving the
clinical trial environment in both countries.
There were also a number of limitations to our present
study. First, although both university hospitals are
viewed as representative, the survey cannot wholly re-
flect the view of all doctors in both countries. Second,
the differences in the response rate and the different
composition of respondents in their age and position at
KUHP and SNUH may have contributed to a selection
bias. These differences could have posed as confounding
factors when comparing the survey results from both
countries in our study. Third, a selection bias exists
whereby the results are skewed in the direction of those
who were vocal about their opinions relating to clinical
trials in both university hospitals. Fourth, the question-
naire was explained and handed out to staff by depart-
mental directors, which could create social pressure to
be active in clinical trials. Such professional and social
pressure might lead physicians to respond to a survey insocially desirable ways. Fifth, the issues relating to clin-
ical trial ethics were not covered by the questionnaire.
While a knowledge test regarding the Declaration of
Helsinki was provided, there were no questions on how
doctors felt about possible conflicts of interest especially
relating to randomised trials [32-34]. Finally, although
using a structured anonymous questionnaire system
helped in obtaining unbiased opinions from the doctors,
this made it impossible to further explore in depth the
individual merits and disadvantages regarding clinical
trials for the doctors.
Conclusions
Our results revealed that there might be approaches at
two different levels to increase the activation of clinical
trials. One is a social level approach involving establish-
ment of better clinical trial infrastructure and providing
sufficient clinical research professionals. The other is an
individual-based approach targeted to increase the moti-
vations of physicians toward participating in and conduct-
ing clinical trials. Both approaches would be necessary to
maximally increase clinical trial activity.
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